HONG KONG, SHANGHAI, CHINA & FLORHAM PARK, NEW JERSEY, USA | November 18, 2026
HUTCHMED (China) Limited has announced promising preclinical findings for HMPL-A830, an investigational antibody-targeted therapy conjugate (ATTC) designed to target epidermal growth factor receptor (EGFR) and KRAS signaling in cancer cells. The findings were presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, taking place from November 18–20, 2026, in Barcelona, Spain. HMPL-A830 represents a novel approach to targeted cancer treatment by combining an EGFR-directed antibody with a potent pan-KRAS small-molecule inhibitor payload. The development aims to address important limitations associated with existing KRAS-targeted therapies, including treatment resistance, limited activity across different KRAS mutations and systemic toxicity. The latest research demonstrates broad antitumor activity across multiple KRAS-altered tumor models, supporting further clinical investigation of this candidate.
HMPL-A830 Demonstrates Broad Antitumor Activity
HMPL-A830 is a first-in-class Antibody-Targeted Therapy Conjugate (ATTC) that combines an anti-EGFR antibody with a selective and potent KRAS inhibitor payload. The antibody component is designed to recognize EGFR-expressing tumor cells and facilitate targeted delivery of the therapeutic payload. The approach also aims to simultaneously inhibit EGFR and KRAS signaling, two important pathways involved in cancer cell growth, survival and resistance to treatment.In laboratory studies, the pan-KRAS inhibitor demonstrated a dual-action mechanism, blocking both active (ON) and inactive (OFF) states of KRAS. This mechanism is intended to overcome adaptive signaling and resistance mechanisms that can limit the effectiveness of conventional KRAS inhibitors. Preclinical testing demonstrated potent antiproliferative activity across 55 tumor cell lines containing different KRAS alterations, including G12C, G12D, G12V and G13D mutations, as well as amplification of wild-type KRAS.The candidate also demonstrated high binding affinity and rapid internalization into EGFR-positive tumor cells. Researchers observed a bystander killing effect, in which neighboring EGFR-negative tumor cells were also affected by the treatment. Additionally, HMPL-A830 maintained antibody-dependent cellular cytotoxicity (ADCC) activity, an immune-mediated mechanism that can contribute to the destruction of cancer cells. These findings highlight the potential of the ATTC platform to combine targeted drug delivery with multiple complementary antitumor mechanisms.
Mouse Studies Show Durable Tumor Regression
Further preclinical investigations evaluated HMPL-A830 across several mouse tumor models containing EGFR-positive tumors with KRAS alterations. The candidate demonstrated dose-dependent and robust antitumor activity, with more durable tumor regressions than KRAS G12C inhibitors in the reported comparative studies.The research also compared HMPL-A830 with several other treatment approaches, including its unconjugated antibody component, a pan-RAS inhibitor administered alone or in combination with cetuximab, and a TROP2-targeted topoisomerase I inhibitor antibody-drug conjugate. HMPL-A830 demonstrated stronger antitumor activity in the reported models.Pharmacokinetic and pharmacodynamic (PK/PD) analyses further indicated sustained inhibition of downstream EGFR/KRAS signaling. Importantly, the drug-to-antibody ratio (DAR) remained stable in mouse, monkey and human plasma during the preclinical evaluations, supporting the stability of the conjugate under the conditions tested.Although these results provide encouraging evidence for further development, they are based on laboratory and animal studies. They do not establish clinical safety or effectiveness in humans.
GSK Collaboration and Global Phase I Development
HMPL-A830 is currently being evaluated in the Phase Ia portion of an ongoing global Phase I clinical trial involving patients with unresectable, advanced or metastatic solid tumors. The study is designed to assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary antitumor activity. The trial represents the transition of HMPL-A830 from preclinical research into early-stage human clinical development.The candidate is also supported by a strategic pharmaceutical collaboration. In September 2026, HUTCHMED entered into an exclusive development and licensing agreement with a subsidiary of GSK plc, granting GSK worldwide development and commercialization rights outside Mainland China, Hong Kong, Macau and Taiwan. Under the agreement, HUTCHMED is responsible for the global Phase I development program, while GSK will lead subsequent clinical development and commercialization activities in its licensed territories.The presentation of HMPL-A830’s preclinical findings at the international oncology conference highlights continued innovation in targeted cancer therapies and precision oncology. By combining EGFR-directed delivery with pan-KRAS inhibition, HUTCHMED aims to develop a differentiated treatment approach for patients with KRAS-driven cancers. The ongoing Phase I study will be important in determining whether the encouraging preclinical findings translate into meaningful clinical benefits.
Source: HUTCHMED, GSK press release


